The DOI matches its Crossref record.
Stem cell treatment for acute myocardial infarction
Abstract
BACKGROUND: Stem cell therapy offers a promising approach to the regeneration of damaged vascular and cardiac tissue after acute myocardial infarction (AMI). This has resulted in multiple randomised controlled trials (RCTs) worldwide. OBJECTIVES: To critically evaluate evidence from RCTs on the effectiveness of adult bone marrow-derived stem cells (BMSC) to treat acute myocardial infarction (AMI). SEARCH METHODS: This Cochrane review is an update of a previous one (published in 2008). MEDLINE (1950 to January 2011), EMBASE (1974 to January 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2011), CINAHL (1982 to January 2011) and the Transfusion Evidence Library (1980 to January 2011) were searched. In addition, several international and ongoing trial databases were searched and handsearching of relevant conference proceedings undertaken to January 2011. SELECTION CRITERIA: RCTs comparing autologous stem/progenitor cells with no autologous stem/progenitor cells in patients diagnosed with AMI were eligible. DATA COLLECTION AND ANALYSIS: Two authors independently screened all references, assessed trial quality and extracted data. Meta-analyses using a random-effects model were conducted and heterogeneity was explored for the primary outcome using sub-group analyses. MAIN RESULTS: Thirty-three RCTs (1765 participants) were eligible for inclusion. Stem/progenitor cell treatment was not associated with statistically significant changes in the incidence of mortality (RR 0.70, 95% CI 0.40 to 1.21) or morbidity (the latter measured by re-infarction, hospital re-admission, restenosis and target vessel revascularisation). A considerably high degree of heterogeneity has been observed among the included trials. In short-term follow up, stem cell treatment was observed to improve left ventricular ejection fraction (LVEF) significantly (WMD 2.87, 95% CI 2.00 to 3.73). This improvement in LVEF was maintained over long-term follow up of 12 to 61 months (WMD 3.75, 95% CI 2.57 to 4.93). With certain measurements and at certain times, stem cell treatment was observed to reduce left ventricular end systolic and end diastolic volumes (LVESV & LVEDV) and infarct size significantly in long-term follow up. There was a positive correlation between mononuclear cell dose infused and the effect on LVEF measured by magnetic resonance imaging. A correlation between timing of stem cell treatment and effect on LVEF measured by left ventricular angiography was also observed. AUTHORS' CONCLUSIONS: Despite the high degree of heterogeneity observed, the results of this systematic review suggest that moderate improvement in global heart function is significant and sustained long-term. However, because mortality rates after successful revascularization of the culprit arteries are very low, larger number of participants would be required to assess the full clinical effect of this treatment. Standardisation of methodology, cell dosing and cell product formulation, timing of cell transplantation and patient selection may also be required in order to reduce the substantial heterogeneity observed among the included studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Exosomes and Cardiac Repair After Myocardial Infarction
Sahoo, S., & Losordo, D. W. (2014) · Circulation Research · doi:10.1161/circresaha.114.300639 · Cited by 523
Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction
Westman, P. C., Lipinski, M. J., Luger, D., Waksman, R., Bonow, R. O., Wu, E., & Epstein, S. E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.073 · Cited by 506
Stem cell treatment for acute myocardial infarction
Fisher, S. A., Zhang, H., Doree, C., Mathur, A., & Martin-Rendon, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006536.pub4 · Cited by 445
Self-citationTraverse, J. H., Henry, T. D., Pepine, C. J., Willerson, J. T., Zhao, D. X. M., Ellis, S. G., Forder, J. R., Anderson, R. D., Hatzopoulos, A. K., Penn, M. S., et al. (2012) · JAMA · doi:10.1001/jama.2012.28726 · Cited by 392
Cardiac Stem Cell Therapy and the Promise of Heart Regeneration
Garbern, J. C., & Lee, R. T. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.05.008 · Cited by 369
Golpanian, S., Wolf, A., Hatzistergos, K. E., & Hare, J. M. (2016) · Physiological Reviews · doi:10.1152/physrev.00019.2015 · Cited by 343
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marban, E., Assmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313
Cell therapy for cardiac repair—lessons from clinical trials
Behfar, A., Crespo-Diaz, R., Terzic, A., & Gersh, B. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.9 · Cited by 292
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
EPMA, Golubnitschaja, O., & Costigliola, V. (2012) · EPMA Journal · doi:10.1186/1878-5085-3-14 · Cited by 267
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
Fisher, S. A., Doree, C., Mathur, A., Taggart, D. P., & Martin-Rendon, E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007888.pub3 · Cited by 254
Self-citationHigh statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes
Alba, A. C., Alexander, P. E., Chang, J., MacIsaac, J., DeFry, S., & Guyatt, G. H. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.09.005 · Cited by 129
“Reasons for this increase in variability, examples of which we present in Table 1, include early studies enrolling broad or restricted patient populations and later studies testing the intervention in subgroups (if initially broad) [17] or wider populations (if initially narrow); early studies using more similar inter…”
BackgroundResultSong, Y.-S., Joo, H.-W., Park, I.-H., Shen, G.-Y., Lee, Y., Shin, J. H., Kim, H., & Kim, K.-S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179972 · Cited by 53
Metadata
- Authors
- Clifford, D. M., Fisher, S. A., Brunskill, S. J., Doree, C., Mathur, A., Watt, S., & Martin-Rendon, E.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2012-02-15
- Issue
- 2
- Pages
- CD006536-CD006536
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4211119432
- Cited by
- 240
- References
- 0
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.